Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Labianca

Showing results (141-150 of 174) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
Cancers|May 28, 2020
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR TherapyRiccardo Giampieri, Pina Ziranu, Bruno Daniele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and OxaliplatinElisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
Tumori|October 30, 2016
Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statementStefania Gori, Carmine Pinto, Caterina Caminiti, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2025
Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancerPatricia Gomez-Rosas, Magdolna Nagy, Henry M H Spronk, et al.
Journal of Thrombosis and Haemostasis : JTH|April 13, 2023
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohortCristina Verzeroli, Cinzia Giaccherini, Laura Russo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerTimothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Cancers|September 28, 2023
A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer PatientsPatricia Gomez-Rosas, Cinzia Giaccherini, Laura Russo, et al.
The New England Journal of Medicine|March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon CancerAxel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Pageof 18

Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
Cancers|May 28, 2020
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR TherapyRiccardo Giampieri, Pina Ziranu, Bruno Daniele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and OxaliplatinElisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
Tumori|October 30, 2016
Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statementStefania Gori, Carmine Pinto, Caterina Caminiti, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2025
Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancerPatricia Gomez-Rosas, Magdolna Nagy, Henry M H Spronk, et al.
Journal of Thrombosis and Haemostasis : JTH|April 13, 2023
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohortCristina Verzeroli, Cinzia Giaccherini, Laura Russo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerTimothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Cancers|September 28, 2023
A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer PatientsPatricia Gomez-Rosas, Cinzia Giaccherini, Laura Russo, et al.
The New England Journal of Medicine|March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon CancerAxel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Pageof 18